During her Ph.D. studies, Dr. Hur conducted research on nanozyme-based anticancer nanocomposites for cancer therapy, as well as in vitro analysis using an electrochemical cell chip. After completing her Ph.D., she focused on engineering tumor-targeting nanocomposites for delivering therapeutic and imaging agents. In July 2023, she joined the Bioengineering & Nanomedicine Program (BENMD) at Harvard Medical School and Massachusetts General Hospital. In the Choi lab, she is currently a member of the image-guided drug delivery system team and is investigating the combination of drug targeting and imaging using polymer-based nanoparticles and small molecule fluorophores via both in vitro cell culture experiments and in vivo mouse models.